Non-paroxysmal permanent ataxia, spasticity, dysarthria, and dystonia had been reasonably improved in four individuals and slightly improved within the remaining two. Preprandial transient aggravation of neurological signs fully disappeared in all members. For the treatment of GLUT1-DS, the MAD is much less restrictive, extra palatable, and easier to maintain than the traditional ketogenic food plan, however its effectiveness was comparable. Thus, MAD therapy is promising for individuals with GLUT1-DS and their families.